BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
13 May 2019 - 3:00PM
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading
developer of adult stem cell technologies for neurodegenerative
diseases, announced today that Chaim Lebovits, president and CEO,
will provide an update on the Company’s two clinical trials of
NurOwn® (the Phase 3 study in amyotrophic lateral sclerosis (ALS)
and the Phase 2 study in Progressive Multiple Sclerosis (MS),
during the 14th Annual World Advanced Therapy and Regenerative
Medicine Congress, taking place in London, England. Mr.
Lebovits will be participating in a Round Table session titled:
“Stem Cells for Neurological Applications,” and then join a Panel
discussion titled: “Clinical Development of Next Generation
Cellular Therapeutics.” Mr. Lebovits will also be hosting
institutional investor and industry leader partnering meetings
during the Congress.
Round Table: Stem Cells for Neurological
Applications |
Date: |
Thursday, May 16 |
Time: |
12:10pm BST |
Location: |
Business Design Centre, London (Technology and Strategy Roundtables
– Table 4) |
Presenter: |
Chaim Lebovits, Chief Executive Officer |
|
|
Panel Discussion: Clinical Development of Next Generation
Cellular Therapeutics |
Date: |
Thursday, May 16 |
Time: |
02.35pm BST |
Location: |
Business Design Centre, London (Clinical Trials: Cell Therapy &
CAR-T - Track 4) |
Presenter: |
Chaim Lebovits, Chief Executive Officer |
|
|
About the World Advanced Therapies &
Regenerative Medicine CongressThe 14th annual World
Advanced Therapies & Regenerative Medicine Congress will bring
together 1000+ attendees and explores the rapidly developing world
of next generation therapeutics and advanced therapy medical
products (ATMPs). From clinical development to pricing,
reimbursement and market access this congress will bring the most
exciting case studies and new data for immunotherapy, cell therapy,
gene therapy, CARs and bioprocessing. Experts in every area will
help companies tackle the process and regulatory hurdles of
developing all new therapeutic formats all the way through
manufacture and into the clinic. This year’s conference will
take place May 15 – 17 at the Business Design Center, London.
About BrainStorm Cell Therapeutics
Inc. BrainStorm Cell Therapeutics Inc. is
a leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Orphan
Drug status designation from the U.S. Food and Drug Administration
(U.S. FDA) and the European Medicines Agency (EMA) in ALS.
BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS
(NCT03280056), investigating repeat-administration of autologous
MSC-NTF cells at six sites in the U.S., supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing for
U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm
also recently received U.S. FDA clearance to initiate a Phase 2
open-label multicenter trial in progressive Multiple Sclerosis. The
Phase 2 study of autologous MSC-NTF cells in patients with
progressive MS (NCT03799718) started enrollment in March 2019. For
more information, visit the company's website at
www.brainstorm-cell.com
Safe-Harbor Statements
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve
risks and uncertainties that could cause BrainStorm Cell
Therapeutics Inc.'s actual results to differ materially from
those stated or implied by such forward-looking statements. Terms
and phrases such as "may", "should", "would", "could", "will",
"expect", "likely", "believe", "plan", "estimate", "predict",
"potential", and similar terms and phrases are intended to identify
these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on
Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Corporate: Uri Yablonka Chief
Business Officer BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188 uri@brainstorm-cell.com
Investors: Michael Levitan Solebury
Trout Phone: 646-378-2920
mlevitan@soleburytrout.com
Media: Sean Leous Westwicke Public
Relations Phone: 646-677-1839 sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024